Perspectives on coronary risk. Part II: these nurse-specialists are changing the risk picture.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to J Dunbar.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Thirty-six evaluable patients with carcinoma of the uterine cervix or vagina not amenable to surgery or radiation therapy were treated with doxorubicin, cyclophosphamide, and 5-fluorouracil; 16.5% of the patients responded, with 2.7% having a complete response. Only four (11.17%) of the 36 patients are alive, all with persistent malignancy, and none of the responders are alive. Because of the low response and survival rates, this combination is not recommended for women with recurrent cervical or vaginal carcinoma.